DK1496944T3 - Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteiner - Google Patents
Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteinerInfo
- Publication number
- DK1496944T3 DK1496944T3 DK03786493T DK03786493T DK1496944T3 DK 1496944 T3 DK1496944 T3 DK 1496944T3 DK 03786493 T DK03786493 T DK 03786493T DK 03786493 T DK03786493 T DK 03786493T DK 1496944 T3 DK1496944 T3 DK 1496944T3
- Authority
- DK
- Denmark
- Prior art keywords
- vectors
- expression systems
- proteins
- sapsid
- raav
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/858—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37731502P | 2002-05-01 | 2002-05-01 | |
PCT/US2003/013583 WO2004027019A2 (en) | 2002-05-01 | 2003-05-01 | Improved raav expression systems for genetic modification of specific capsid proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1496944T3 true DK1496944T3 (da) | 2008-12-01 |
Family
ID=32030574
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03786493T DK1496944T3 (da) | 2002-05-01 | 2003-05-01 | Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteiner |
Country Status (11)
Country | Link |
---|---|
US (2) | US8802080B2 (da) |
EP (1) | EP1496944B1 (da) |
AT (1) | ATE405295T1 (da) |
AU (1) | AU2003295312B2 (da) |
CA (1) | CA2483624A1 (da) |
DE (1) | DE60323078D1 (da) |
DK (1) | DK1496944T3 (da) |
HK (1) | HK1071518A1 (da) |
NZ (2) | NZ561656A (da) |
SI (1) | SI1496944T1 (da) |
WO (1) | WO2004027019A2 (da) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ561656A (en) | 2002-05-01 | 2009-03-31 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
US20060093589A1 (en) * | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
US20040179028A1 (en) * | 2003-03-12 | 2004-09-16 | Fuji Photo Film Co., Ltd. | Pixel defect correcting method, color mura correcting method and image display device |
CA2500523A1 (en) * | 2003-05-01 | 2004-11-18 | University Of Florida Research Foundation, Inc. | Vp2-modified raav vector compositions and uses therefor |
EP1486567A1 (en) * | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
ES2329636B2 (es) | 2006-02-17 | 2010-07-26 | Universitat De Valencia, Estudi General (Participa Con El 70%) | Uso del factor pedf para inducir la auto-renovacion de celulas madre. |
EP3492596A1 (en) | 2007-04-09 | 2019-06-05 | University of Florida Research Foundation, Inc. | Raav vector compositions having tyrosine-modified capsid proteins and methods for use |
US9611302B2 (en) | 2007-04-09 | 2017-04-04 | University Of Florida Research Foundation, Inc. | High-transduction-efficiency RAAV vectors, compositions, and methods of use |
US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
CN101951925A (zh) * | 2008-02-20 | 2011-01-19 | 建新公司 | 血管发生抑制 |
CN102159713A (zh) | 2008-05-20 | 2011-08-17 | Eos神经科学公司 | 用于递送光敏蛋白的载体和使用方法 |
WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
PT2403867T (pt) | 2009-03-04 | 2019-08-29 | Deutsches Krebsforsch | Proteína de ativação de montagem (aap) e a sua utilização para o fabrico de partículas de parvovírus essenciais consistindo de vp3 |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
MX359070B (es) | 2010-12-01 | 2018-09-13 | Alderbio Holdings Llc | Composiciones anti-ngf y uso de las mismas. |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
EP3539568A1 (en) * | 2011-11-22 | 2019-09-18 | The Children's Hospital of Philadelphia | Virus vectors for highly efficient transgene delivery |
US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
KR102380265B1 (ko) | 2013-07-22 | 2022-03-29 | 더 칠드런스 호스피탈 오브 필라델피아 | 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 |
CN104592364B (zh) * | 2013-10-30 | 2018-05-01 | 北京大学 | 定点突变和定点修饰的腺相关病毒、其制备方法及应用 |
US11185854B2 (en) * | 2013-12-06 | 2021-11-30 | Johnson Matthey Public Limited Company | Cold start catalyst and its use in exhaust systems |
GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
CA2941640A1 (en) | 2014-03-04 | 2015-09-11 | University Of Florida Research Foundation, Inc. | Improved raav vectors and methods for transduction of photoreceptors and rpe cells |
IL292951B1 (en) | 2014-05-02 | 2024-06-01 | Genzyme Corp | AAV vectors for gene therapy in the central nervous system and retina |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
PT3198018T (pt) * | 2014-09-24 | 2021-02-24 | Hope City | Variantes dos vetores de vírus adenoassociados para edição do genoma de alta eficácia e métodos da mesma |
CA2966620A1 (en) | 2014-11-05 | 2016-05-12 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
EP3031820A1 (en) | 2014-12-08 | 2016-06-15 | Life Science Inkubator | JC Polyomavirus VLP (virus-like particle) with a targeting peptide |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
US20180030096A1 (en) | 2015-02-03 | 2018-02-01 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
WO2016133917A1 (en) | 2015-02-16 | 2016-08-25 | University Of Florida Research Foundation | Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes |
US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
JP6985250B2 (ja) | 2015-05-16 | 2021-12-22 | ジェンザイム・コーポレーション | 深部イントロン突然変異の遺伝子編集 |
CN108138159A (zh) | 2015-06-23 | 2018-06-08 | 费城儿童医院 | 经修饰的因子ix、以及用于基因转移到细胞、器官和组织的组合物、方法和用途 |
PT3356390T (pt) | 2015-09-28 | 2021-04-21 | Univ Florida | Métodos e composições para vetores virais que se evadem a anticorpos |
US20190071681A1 (en) * | 2016-02-26 | 2019-03-07 | University Of Florida Research Foundation, Incorporated | Aav heparin mutants that display significantly improved eye and brain transduction |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
CN109476707B (zh) | 2016-05-13 | 2022-12-02 | 4D分子治疗有限公司 | 腺相关病毒变体衣壳和其使用方法 |
SG11201809643UA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
KR102392236B1 (ko) | 2016-05-18 | 2022-05-03 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
MX2019001938A (es) | 2016-08-15 | 2019-07-04 | Genzyme Corp | Metodos para detectar aav. |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
WO2018075798A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
EA038695B1 (ru) | 2017-02-15 | 2021-10-06 | Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл | Способы и композиции для переноса генов по сосудистой сети |
CN110392607A (zh) * | 2017-03-13 | 2019-10-29 | 三菱化学株式会社 | 过渡金属负载沸石和其制造方法以及氮氧化物净化用催化剂和其使用方法 |
CN110770346B (zh) * | 2017-03-15 | 2024-01-12 | 北卡罗来纳-查佩尔山大学 | 多倍体腺相关病毒载体及其制备和使用方法 |
US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
WO2018204803A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
CN110913866A (zh) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
UA127455C2 (uk) | 2017-09-20 | 2023-08-30 | 4Д Молекьюлар Терапьютикс Інк. | Капсид аденоасоційованого вірусу і спосіб його застосування |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
EP4219695A3 (en) | 2017-11-27 | 2024-01-17 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
WO2019158619A1 (en) * | 2018-02-15 | 2019-08-22 | Bjoerklund Tomas | Modified viral capsids |
BR112020020266A2 (pt) | 2018-04-03 | 2021-01-19 | Stridebio, Inc. | Vetores de vírus com evasão de anticorpos |
JP2021522775A (ja) * | 2018-05-07 | 2021-09-02 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill | 合理的なポリプロイド性アデノ随伴ウイルスベクターならびにその製造法および使用法 |
US11821009B2 (en) | 2018-05-15 | 2023-11-21 | Cornell University | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
US20210317478A1 (en) * | 2018-08-21 | 2021-10-14 | Massachusetts Eye And Ear Infirmary | Compositions and methods for modulating transduction efficiency of adeno-associated viruses |
US20220154211A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
MX2021010149A (es) | 2019-02-25 | 2021-09-14 | Novartis Ag | Composiciones y metodos para tratar la distrofia cristalina de bietti. |
CA3133453A1 (en) | 2019-03-21 | 2020-09-24 | Daniel Mccoy | Recombinant adeno-associated virus vectors |
US20210082541A1 (en) * | 2019-08-31 | 2021-03-18 | Wyatt Technology Corporation | Measuring attributes of a viral gene delivery vehicle sample via separation |
BR112022006530A2 (pt) | 2019-10-17 | 2022-07-05 | Stridebio Inc | Vetores virais adenoassociados para o tratamento da doença de niemann-pick tipo c |
WO2024006433A1 (en) * | 2022-06-30 | 2024-01-04 | Carnegie Mellon University | Method for production of virus-like particles for gene delivery |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994029469A2 (en) * | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
US6204059B1 (en) * | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5741683A (en) * | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
JP2001500376A (ja) * | 1996-09-06 | 2001-01-16 | カイロン コーポレイション | 組換えaavベクターを使用する治療分子の肝臓特異的送達のための方法および組成物 |
US6221646B1 (en) * | 1997-07-31 | 2001-04-24 | Chiron Corporation | Materials and methods for simplified AAV production |
EP1183051A2 (en) | 1999-03-15 | 2002-03-06 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6329181B1 (en) * | 2000-08-07 | 2001-12-11 | Neurologix, Inc. | Helper functions for recombinant vector production |
AU2001292881A1 (en) | 2000-09-20 | 2002-04-02 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US6962815B2 (en) * | 2001-01-05 | 2005-11-08 | Children's Hopital Inc. | AAV2 vectors and methods |
US6692815B2 (en) * | 2001-06-15 | 2004-02-17 | Vinylex Corporation | Extruded plastic lumber and method of manufacture |
US6723551B2 (en) * | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
US20060292117A1 (en) * | 2002-04-17 | 2006-12-28 | Loiler Scott A | Improved rAAv vectors |
NZ561656A (en) | 2002-05-01 | 2009-03-31 | Univ Florida | Improved rAAV expression systems for genetic modification of specific capsid proteins |
AU2003265855A1 (en) * | 2002-08-28 | 2004-03-19 | University Of Florida | Modified aav |
CA2500523A1 (en) | 2003-05-01 | 2004-11-18 | University Of Florida Research Foundation, Inc. | Vp2-modified raav vector compositions and uses therefor |
-
2003
- 2003-05-01 NZ NZ561656A patent/NZ561656A/en unknown
- 2003-05-01 AT AT03786493T patent/ATE405295T1/de not_active IP Right Cessation
- 2003-05-01 US US10/513,059 patent/US8802080B2/en active Active
- 2003-05-01 NZ NZ536274A patent/NZ536274A/en unknown
- 2003-05-01 DE DE60323078T patent/DE60323078D1/de not_active Expired - Fee Related
- 2003-05-01 CA CA002483624A patent/CA2483624A1/en not_active Abandoned
- 2003-05-01 AU AU2003295312A patent/AU2003295312B2/en not_active Ceased
- 2003-05-01 DK DK03786493T patent/DK1496944T3/da active
- 2003-05-01 EP EP03786493A patent/EP1496944B1/en not_active Expired - Lifetime
- 2003-05-01 SI SI200331424T patent/SI1496944T1/sl unknown
- 2003-05-01 WO PCT/US2003/013583 patent/WO2004027019A2/en not_active Application Discontinuation
-
2005
- 2005-05-24 HK HK05104362.7A patent/HK1071518A1/xx not_active IP Right Cessation
-
2014
- 2014-07-08 US US14/326,293 patent/US20150005369A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1071518A1 (en) | 2005-07-22 |
WO2004027019A2 (en) | 2004-04-01 |
NZ536274A (en) | 2008-04-30 |
EP1496944A4 (en) | 2006-03-22 |
SI1496944T1 (sl) | 2009-02-28 |
US20060088936A1 (en) | 2006-04-27 |
ATE405295T1 (de) | 2008-09-15 |
EP1496944B1 (en) | 2008-08-20 |
NZ561656A (en) | 2009-03-31 |
AU2003295312B2 (en) | 2008-08-14 |
EP1496944A2 (en) | 2005-01-19 |
US8802080B2 (en) | 2014-08-12 |
WO2004027019A3 (en) | 2004-08-05 |
US20150005369A1 (en) | 2015-01-01 |
AU2003295312A1 (en) | 2004-04-08 |
CA2483624A1 (en) | 2004-04-01 |
DE60323078D1 (de) | 2008-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1496944T3 (da) | Forbedrede rAAV-ekspressionssystemer til genetisk modificering af specifikke sapsid-proteiner | |
CY1124586T1 (el) | Ομαδες, αλληλουχιες, φορεις αδενο-σχετιζομενου ιου (aav) που περιεχουν αυτον, και οι χρησεις τους | |
PH12020550094A1 (en) | Adeno-associated virus variant capsids and methods of use thereof | |
DE60033293D1 (de) | Neue b7-4 moleküle und deren verwendungen | |
WO2005077333A3 (en) | Gel-based delivery of recombinant adeno-associated virus vectors | |
WO2005005610A3 (en) | Mutant adeno-associated virus virions and methods of use thereof | |
ATE366814T1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
WO2003042362A3 (en) | PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR | |
WO2000046236A3 (en) | Novel rgs-containing molecules and uses thereof | |
DE60031418D1 (de) | 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen | |
ATE480620T1 (de) | Neue pgc-1-isoformen und deren verwendungen | |
ES2226597T1 (es) | Vectores recombinantes virales y no virales que contienen el gen humano de urokinasa del activador del plasminogeno y su utilizacion en el tratamiento de varios tipos de fibrosis hepatica, renal, pulmonar, pancreatica y cardiaca y cicatrices hipertroficas. | |
WO2002002148A3 (en) | Dual recombinant gene therapy compositions and methods of use | |
DK0781344T3 (da) | Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme | |
BR112022003206A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
WO2001083781A3 (en) | 14094, a novel human trypsin family member and uses thereof | |
DK1664315T3 (da) | AAV-vektorer til in vivo genterapi af rheumatoid arthritis | |
WO2001064894A3 (en) | Human phospholipid scramblase-like molecules and uses thereof | |
DE60237236D1 (de) | Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür | |
DE60234047D1 (de) | 15603, ein mitglied der humanen ionenkanal-familie | |
WO2002016568A3 (en) | 46863, a human methyltransferase and uses thereof | |
DE60136832D1 (de) | Atcr-1, eine humane acyltransferase und verwendungen davon | |
WO2001068806A3 (en) | 26934, a novel cytidine deaminase-like molecule and uses thereof | |
AU2001288284A1 (en) | 14189, a human kinase and uses thereof | |
WO2001064908A3 (en) | 14790, a protein kinase and uses therefor |